Hengrui Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
A Phase 1, Study to Evaluate HTI-2088 Tablet
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Hengrui Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03203811
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Hengrui Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02500199
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸University of California, Irvine School of Medicine, Orange, California, United States
© Copyright 2024. All Rights Reserved by MedPath